Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 23, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $179.66 to $12,841,992.00.

Highlighted Stocks Traded by Insiders:

Biocryst Pharmaceuticals (BCRX) - FREE Research Report

Hutson Nancy J, who is Director at Biocryst Pharmaceuticals, bought 10,000 shares at $10.27 on Feb. 23, 2015. Following this transaction, the Director owned 15,891 shares meaning that the stake was boosted by 169.75% with the 10,000-share transaction.

The shares most recently traded at $10.43, up $0.16, or 1.53% since the insider transaction. Historical insider transactions for Biocryst Pharmaceuticals go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 56,899
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 56,899
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 56,899

The average volume for Biocryst Pharmaceuticals has been 872,100 shares per day over the past 30 days. Biocryst Pharmaceuticals has a market cap of $729.4 million and is part of the health care sector and drugs industry. Shares are down 13.57% year-to-date as of the close of trading on Monday.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. Currently, there are 7 analysts who rate Biocryst Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCRX - FREE

TheStreet Quant Ratings

rates Biocryst Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full

Biocryst Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

McGraw Hill Financial (MHFI) - FREE Research Report

Neal Lawrence, who is President, Platts at McGraw Hill Financial, sold 2,990 shares at $105.04 on Feb. 23, 2015. Following this transaction, the President, Platts owned 19,209 shares meaning that the stake was reduced by 13.47% with the 2,990-share transaction.

The shares most recently traded at $103.92, down $1.12, or 1.08% since the insider transaction. Historical insider transactions for McGraw Hill Financial go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 9,755
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 9,755
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 9,755

The average volume for McGraw Hill Financial has been 1.4 million shares per day over the past 30 days. McGraw Hill Financial has a market cap of $28.6 billion and is part of the services sector and diversified services industry. Shares are up 17.03% year-to-date as of the close of trading on Monday.

McGraw Hill Financial, Inc. provides benchmarks and ratings, analytics, data, and research services for the capital, commodities, and commercial markets worldwide. The stock currently has a dividend yield of 1.26%. Currently, there are 8 analysts who rate McGraw Hill Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MHFI - FREE

TheStreet Quant Ratings

rates McGraw Hill Financial as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full

McGraw Hill Financial Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Magellan Midstream Partners L.P (MMP) - FREE Research Report

Selvidge Jeff R, who is Senior Vice President at Magellan Midstream Partners L.P, sold 7,500 shares at $82.50 on Feb. 23, 2015. Following this transaction, the Senior Vice President owned 22,499 shares meaning that the stake was reduced by 25% with the 7,500-share transaction.

The shares most recently traded at $82.81, up $0.31, or 0.37% since the insider transaction. Historical insider transactions for Magellan Midstream Partners L.P go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 12,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 66,866

The average volume for Magellan Midstream Partners L.P has been 798,600 shares per day over the past 30 days. Magellan Midstream Partners L.P has a market cap of $19.0 billion and is part of the basic materials sector and energy industry. Shares are down 0.06% year-to-date as of the close of trading on Monday.

Magellan Midstream Partners, L.P. is engaged in the transportation, storage, and distribution of refined petroleum products and crude oil in the United States. It operates in three segments: Refined Products, Crude Oil, and Marine Storage. The stock currently has a dividend yield of 3.33%. The company has a P/E ratio of 22.6. Currently, there are 7 analysts who rate Magellan Midstream Partners L.P a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMP - FREE

TheStreet Quant Ratings

rates Magellan Midstream Partners L.P as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, solid stock price performance, compelling growth in net income and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Magellan Midstream Partners L.P Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null